Quarterly ResultAug 11, 2026, 04:23 PM
BridgeBio Oncology Q2 Net Loss Widens to $56.5M
AI Summary
BridgeBio Oncology Therapeutics reported a significant widening of its net loss for the second quarter of 2026 to $56.5 million, compared to $28.4 million in the same period last year. This was driven by substantial increases in both research and development and general and administrative expenses. The company's cash and cash equivalents also saw a sharp decline, though management believes existing liquidity is sufficient for at least one year. The de-SPAC transaction completed in August 2025 impacts year-over-year comparisons.
Key Highlights
- Net loss for Q2 2026 widened to $56.5 million, up from $28.4 million in Q2 2025.
- Research and development expenses increased to $49.2 million in Q2 2026 from $27.4 million in Q2 2025.
- General and administrative expenses rose to $11.0 million in Q2 2026 from $2.7 million in Q2 2025.
- Cash and cash equivalents decreased to $54.1 million as of June 30, 2026, from $373.7 million at December 31, 2025.
- Total assets were $376.7 million as of June 30, 2026, down from $448.4 million at December 31, 2025.
- Net cash used in operating activities for H1 2026 was $80.3 million, compared to $42.9 million in H1 2025.
- The company reported $344.1 million in cash, cash equivalents, and marketable securities as of June 30, 2026, sufficient for at least one year.
Price Impact
More from BBOT